Literature DB >> 20419851

Focal periocular carboplatin chemotherapy avoids systemic chemotherapy for unilateral, progressive retinoblastoma.

Theodore Leng1, Colleen M Cebulla, Amy C Schefler, Timothy G Murray.   

Abstract

PURPOSE: The purpose of this study was to report a case of a boy with unilateral, multifocal retinoblastoma who was successfully treated with periocular carboplatin injections for a tumor that progressed despite focal laser ablation.
METHODS: This is an interventional case report. A boy with a paternal history of retinoblastoma and in utero identification of an RB1 mutation was monitored beginning at 2 weeks of age. When the patient was 6 months old, the first tumor was detected and treatment with a direct, ablative, large spot-size diode laser was initiated. During a 38-month period of follow-up, the patient received 23 laser treatments and 3 periocular carboplatin injections (20 mg in 2 mL) to treat 3 tumors in 1 eye.
RESULTS: Initially, diode laser ablation of the tumors produced a favorable involutional response of the tumors, associated with a decrease in size and vascularity. Despite aggressive treatment with 12 consecutive laser treatments for 9.7 months, progressive tumor growth was observed in the superonasal tumor, whereas the other 2 tumors remained quiescent. At that time, a series of three focal periocular injections of carboplatin were administered in combination with continued laser ablation. The tumor regressed with type 4 chorioretinal scarring. No systemic chemotherapy or radiation was required.
CONCLUSION: This case of unilateral, multifocal retinoblastoma was successfully treated solely with diode laser ablation and rescue periocular injections of carboplatin after the failure of laser alone. A trial of periocular carboplatin with laser may be considered in cases of unilateral retinoblastoma that are resistant to laser ablation therapy alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20419851     DOI: 10.1097/iae.0b013e3181d34a8c

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

Review 1.  Current update on retinoblastoma.

Authors:  Samuel K Houston; Timothy G Murray; Stacey Quintero Wolfe; Cristina E Fernandes
Journal:  Int Ophthalmol Clin       Date:  2011

2.  Retinoblastoma major review with updates on Middle East management protocols.

Authors:  Ihab Saad Othman
Journal:  Saudi J Ophthalmol       Date:  2012-04

3.  Safety and efficacy of posterior sub-Tenon's carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds.

Authors:  Azza Mohamed Ahmed Said; Mohamed Gamil Aly; Hazem Omar Rashed; Anwaar Mahmoud Rady
Journal:  Int J Ophthalmol       Date:  2018-03-18       Impact factor: 1.779

4.  Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.

Authors:  Angela Ferrario; Marian Luna; Natalie Rucker; Sam Wong; Ariel Lederman; Jonathan Kim; Charles Gomer
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

5.  Modeling Developmental and Tumorigenic Aspects of Trilateral Retinoblastoma via Human Embryonic Stem Cells.

Authors:  Yishai Avior; Elyad Lezmi; Dorit Yanuka; Nissim Benvenisty
Journal:  Stem Cell Reports       Date:  2017-04-06       Impact factor: 7.765

6.  Early Mechanisms of Chemoresistance in Retinoblastoma.

Authors:  Michelle G Zhang; Jeffim N Kuznetsoff; Dawn A Owens; Ryan A Gallo; Karthik Kalahasty; Anthony M Cruz; Stefan Kurtenbach; Zelia M Correa; Daniel Pelaez; J William Harbour
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

Review 7.  Conservative treatment modalities in retinoblastoma.

Authors:  Bhavna Chawla; Amit Jain; Rajvardhan Azad
Journal:  Indian J Ophthalmol       Date:  2013-09       Impact factor: 1.848

8.  Death by water: precautionary water submersion for intravitreal injection of retinoblastoma eyes.

Authors:  Jasmine H Francis; Xiaoliang L Xu; Y Pierre Gobin; Brian P Marr; Scott E Brodie; David H Abramson
Journal:  Open Ophthalmol J       Date:  2014-05-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.